Clinical trial

Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Breast Cancer

NCT07374796

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

OTHER · Unmapped registry intervention Epigenetic Assay Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Breast Cancer

Design: OBSERVATIONAL · Status: NOT YET RECRUITING · Phase: Not specified

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusNOT_YET_RECRUITING

Study typeOBSERVATIONAL

Start date2026-12-01

PhaseN/A

Conditions

Breast Cancer (Locally Advanced or Metastatic)unresolved

Healthy Volunteers (HV)unresolved

Unhealthy Volunteersunresolved

Breast Cancer Screeningunresolved

Interventions

Epigenetic AssayOTHER

Sponsors & collaborators

University of Maryland, Baltimorelead sponsor

EPOCH Epigenetics, Inccollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07374796 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.